Radiopharmaceutical therapies represent a growing frontier in cancer treatment, combining radioactive isotopes with targeting molecules to deliver precise radiation to tumor cells while sparing healthy tissue. Novartis' Pluvicto, approved in 2022, has demonstrated significant efficacy in extending s

The FDA's rejection does not mark the end of PNT2002's development. Point Biopharma remains committed to addressing the manufacturing concerns and resubmitting its application. If successful, the therapy could still enter the market, providing competition that may drive down costs and improve access

FDA Rejects Radiopharmaceutical Therapy Over Manufacturing Concerns

The US Food and Drug Administration has rejected a radiopharmaceutical therapy developed by Point Biopharma, citing unresolved manufacturing issues. The decision halts the therapy's potential competition with Novartis' Pluvicto, a leading treatment for metastatic castration resistant prostate cancer. The FDA's complete response letter did not raise safety or efficacy concerns but emphasized the need for improved manufacturing processes before approval.

The FDA has issued a complete response letter to Point Biopharma, rejecting its radiopharmaceutical therapy PNT2002 for the treatment of metastatic castration resistant prostate cancer. The decision, announced on June 2, 2025, surprised analysts who had anticipated approval, given the therapy's potential to rival Novartis' Pluvicto, a blockbuster treatment in the same class.

The agency cited manufacturing deficiencies as the primary reason for the rejection, without raising concerns about the therapy's safety or efficacy. Point Biopharma stated it is working closely with the FDA to address the issues and plans to resubmit the application as soon as possible.